DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes

艾塞那肽 医学 血糖性 2型糖尿病 内科学 不利影响 糖尿病 人口 杜拉鲁肽 减肥 恶心 内分泌学 低血糖 胃肠病学 肥胖 环境卫生
作者
Thomas Blevins,John R. Pullman,Jaret L. Malloy,Ping Yan,Kristin Taylor,Christine T. Schulteis,MICHAEL E. TRAUTMANN,Lisa Porter
出处
期刊:The Journal of Clinical Endocrinology and Metabolism [Oxford University Press]
卷期号:96 (5): 1301-1310 被引量:445
标识
DOI:10.1210/jc.2010-2081
摘要

CONTEXT: We wanted to understand the effects of once-weekly vs. twice-daily glucagon-like peptide-1 receptor agonism for treatment of patients with type 2 diabetes. OBJECTIVE: The objective of the study was to compare effects of exenatide once weekly (ExQW) and exenatide twice daily (ExBID) on glycemic control, body weight, and safety. DESIGN: This was a 24-wk, randomized, open-label, comparator-controlled study. SETTING: The study was conducted at 43 sites in the United States. PATIENTS: The study population was 252 intent-to-treat patients with type 2 diabetes [baseline (mean ± SD): glycosylated hemoglobin (HbA1c) 8.4 ± 1.2%, fasting plasma glucose 171 ± 47 mg/dl, weight 96 ± 20 kg] that were drug naïve (19%) or previously treated with one (47%) or multiple (35%) oral antidiabetic medications. INTERVENTIONS: Interventions included ExQW 2 mg for 24 wk or ExBID 5 μg for 4 wk followed by ExBID 10 μg for 20 wk. MAIN OUTCOME MEASURE: The change in HbA1c from baseline to wk 24 was measured. RESULTS: At 24 wk, ExQW produced significantly greater changes from baseline (least squares mean ± SE) vs. ExBID in HbA1c (-1.6 ± 0.1% vs. -0.9 ± 0.1%; P < 0.0001) and fasting plasma glucose (-35 ± 5 mg/dl vs. -12 ± 5 mg/dl; P = 0.0008). Similar reductions in mean body weight from baseline to wk 24 were observed in both groups (-2.3 ± 0.4 kg and -1.4 ± 0.4 kg). Both treatments were generally well tolerated. Transient and predominantly mild to moderate nausea, the most frequent adverse event, was less common with ExQW (14%) than with ExBID (35%). Injection-site reactions were infrequent, but more common with ExQW. No major hypoglycemia occurred. CONCLUSIONS: Continuous glucagon-like peptide-1 receptor agonism with ExQW resulted in superior glycemic control, with less nausea, compared with ExBID in patients with type 2 diabetes. Both groups lost weight.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Z777发布了新的文献求助10
刚刚
小徐完成签到,获得积分10
1秒前
zgw发布了新的文献求助10
1秒前
yrll完成签到,获得积分10
1秒前
李科完成签到 ,获得积分10
1秒前
rhea发布了新的文献求助10
1秒前
知了完成签到,获得积分10
1秒前
明亮夜云完成签到,获得积分10
2秒前
老帅比发布了新的文献求助10
2秒前
chen完成签到,获得积分10
3秒前
3秒前
Yin发布了新的文献求助10
3秒前
1b发布了新的文献求助30
3秒前
3秒前
3秒前
爱笑灵雁发布了新的文献求助10
3秒前
黎敏完成签到,获得积分10
3秒前
4秒前
万能图书馆的应助被星空采纳,获得10
4秒前
junjun2011完成签到 ,获得积分10
4秒前
4秒前
wjjjj完成签到,获得积分10
4秒前
River完成签到,获得积分10
4秒前
QQ发布了新的文献求助10
5秒前
5秒前
珍珍发布了新的文献求助10
6秒前
李健的应助被科研人采纳,获得10
6秒前
Hello的应助被科研通管家采纳,获得10
6秒前
星先生完成签到 ,获得积分10
6秒前
6秒前
思源的应助被科研通管家采纳,获得10
6秒前
无花果的应助被科研通管家采纳,获得10
6秒前
乐乐的应助被科研通管家采纳,获得10
6秒前
香蕉觅云的应助被科研通管家采纳,获得10
6秒前
wuyouping发布了新的文献求助10
6秒前
赘婿的应助被科研通管家采纳,获得10
7秒前
7秒前
324发布了新的文献求助10
7秒前
FashionBoy的应助被科研通管家采纳,获得10
7秒前
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570485
关于积分的说明 21812623
捐赠科研通 7776592
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557522
邀请新用户注册赠送积分活动 2479162